Trading Profile: Assembly Biosciences, Inc., a biopharmaceutical company, develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus (HBV) and C. difficile-associated infections (CDAD). It is involved in developing core protein allosteric modulators that modulate the HBV core protein, a polyfunctional viral protein, at various complementary points in the viral lifecycle; and microbiome program, a treatment for CDAD, for targeted delivery of complex agents to select regions of the gastrointestinal tract. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in New York, New York.
»»» Detailed Company Profile & Chart
Assembly Biosciences Inc current day financials: 2024-03-28 08:48:58pmSymbol | Name | Purchase price | Last Price | Change | % Change |
---|---|---|---|---|---|
0.00 | |||||
Recent ASMB News from Yahoo Finance & Seeking Alpha
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights »
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating interim data from Phase 1a available in 3Q2024, initiation of Phase 1b in individuals with recurrent genital herpes by end of 2024 and interim Phase 1b data available in 1H2025Gilead Sciences, Inc. partnership supports advancement and strengthening of antiviral pipeline targeting serious viral diseases S
Assembly Biosciences Announces Effective Date of Reverse Stock Split »
– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common s
This Assembly Biosciences Insider Increased Their Holding In The Last Year »
Looking at Assembly Biosciences, Inc.'s ( NASDAQ:ASMB ) insider transactions over the last year, we can see that...
Assembly Biosciences Provides Anticipated Development Milestones for 2024 »
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data anticipated by end of year from first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334)Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead)
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) »
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023. The Company granted Dr. Gaggar non-qualified stock options to purchase 500,000 shares of the Company’s common stock with an exercise price of $0.85 per share, the closing pri
Older Archived News Assembly Biosciences Inc
- Assembly Biosciences to Webcast Upcoming Investor Conferences.
- Assembly Biosciences Presents Clinical Data at Drug Formulation & Bioavailability Summit Showing Its Oral Gemicel(TM) Technolog.
- Assembly Biosciences Expands Senior Leadership Team.
- Clinical Study Shows Assembly Biosciences' Oral Gemicelâ„¢ Technology Can Achieve Targeted Delivery to the Lower GI Tract for M.
- Ventrus Biosciences Files and Commences Mailing of Definitive Proxy Materials for July 10th Annual Meeting.
- ETF’s with exposure to Assembly Biosciences, Inc. : September 21, 2015.
- Clinical Study Shows Assembly Biosciences' Oral Gemicelâ„¢ Technology Can Achieve Targeted Delivery to the Lower GI Tract for Microbiome and Other Applications.
- ASSEMBLY BIOSCIENCES, INC. Financials.
- ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a.
- ASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F.Load More News...